285986-88-1 | Ccg-1423

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$6.00	$4.00
5mg	98%	in stock	$14.00	$10.00
10mg	98%	in stock	$20.00	$14.00
50mg	98%	in stock	$56.00	$39.00
250mg	95%	in stock	$270.00	$189.00

Description

• Catalog Number: AB34334
• Chemical Name: Ccg-1423
• CAS Number: 285986-88-1
• Molecular Formula: C18H13ClF6N2O3
• Molecular Weight: 454.7508
• MDL Number: MFCD01566719
• SMILES: O=C(C(ONC(=O)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)C)Nc1ccc(cc1)Cl
• NSC Number: 742825

Computed Properties

• Complexity: 586
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 30
• Hydrogen Bond Acceptor Count: 9
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 5
• Undefined Atom Stereocenter Count: 1
• XLogP3: 4.9

Literature

• Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.

  The Journal of pharmacology and experimental therapeutics 20140601

• Redox modification of nuclear actin by MICAL-2 regulates SRF signaling.

  Cell 20140130

• Optimization of novel nipecotic bis(amide) inhibitors of the Rho/MKL1/SRF transcriptional pathway as potential anti-metastasis agents.

  Bioorganic & medicinal chemistry letters 20130701

• Increased SRF transcriptional activity in human and mouse skeletal muscle is a signature of insulin resistance.

  The Journal of clinical investigation 20110301

• Combination of small molecules enhances differentiation of mouse embryonic stem cells into intermediate mesoderm through BMP7-positive cells.

  Biochemical and biophysical research communications 20100319

• Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423.

  Bioorganic & medicinal chemistry letters 20100115

• Signaling through Rho GTPase pathway as viable drug target.

  Current medicinal chemistry 20090101

• CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling.

  Molecular cancer therapeutics 20070801